Skip to main content

Table 4 Subgroup analysis based on different standard

From: The value of kidney injury molecule 1 in predicting acute kidney injury in adult patients: a systematic review and Bayesian meta-analysis

Studies Sensitivity (95% CrI) Specificity (95% CrI) + LR (95% CrI) − LR (95% CrI) DOR (95% CrI) RD (95% CrI) AUC (95% CrI)
All studies (14) 0.74 (0.62–0.84) 0.84 (0.76–0.90) 4.58 (2.78–9.47) 0.34 (0.23–0.46) 15.22 (6.74–42.20) 0.55 (0.43–0.70) 0.62 (0.41–0.76)
Study design
 Prospective (9) 0.65 (0.51–0.81) 0.76 (0.70–0.82) 2.75 (2.47–3.21) 0.47 (0.24–0.62) 6.68 (4.00–13.18) 0.41 (0.30–0.56) 0.73 (0.67–0.85)
 Non-prospective (5) 0.82 (0.66–0.92) 0.91 (0.74–0.99) 9.36 (2.48–24.05) 0.17 (0.07–0.27) 57.21 (16.26–134.38) 0.67 (0.53–0.78) 0.69 (0.30–0.95)
Blinding or not
 Blinding (5) 0.68 (0.43–0.89) 0.76 (0.68–0.82) 2.97 (2.49–3.53) 0.37 (0.24–0.55) 9.18 (4.62–14.49) 0.48 (0.35–0.58) 0.76 (0.64–0.82)
 Non-blinding (9) 0.77 (0.65–0.88) 0.88 (0.78–0.96) 6.29 (3.89–12.03) 0.25 (0.17–0.32) 28.64 (12.26–72.31) 0.65 (0.55–0.77) 0.64 (0.24–0.89)
Population settings
 CPB surgery (4) 0.73 (0.45–0.93) 0.77 (0.62–0.90) 4.06 (2.10–7.53) 0.41 (0.31–0.64) 11.75 (3.50–23.51) 0.47 (0.27–0.61) 0.75 (0.49–0.90)
 Emergency and critical patients (4) 0.62 (0.365–0.857) 0.79 (0.66–0.91) 3.79 (1.00–6.96) 0.44 (0.22–0.72) 13.25 (2.82–31.69) 0.45 (0.22–0.68) 0.61 (0.44–0.80)
 Others (6) 0.80 (0.66–0.91) 0.89 (0.75–0.97) 7.73 (5.28–13.56) 0.18 (0.16–0.22) 44.44 (24.23–85.74) 0.71 (0.66–0.79) 0.75 (0.54–0.91)
Assay method
 ELISA (12) 0.78 (0.68–0.88) 0.85 (0.75–0.92) 5.59 (3.05–10.18) 0.26 (0.15–0.34) 25.04 (10.33–65.82) 0.63 (0.52–0.77) 0.66 (0.41–0.89)
 Non-ELISA (2) 0.45 (0.27–0.65) 0.80 (0.72–0.86) 2.43 (2.35–2.51) 0.65 (0.62–0.67) 3.78 (3.50–4.05) 0.28 (0.26–0.30) 0.55 (0.53–0.57)
  1. CrI credible interval